Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
113,786
Sort by:
Safilo Far East in Eyewear (Hong Kong, China)
US$ 150.00
Safilo Far East’s strategic focus is to become the leading player in eyewear via a wide product portfolio, which can appealing to a wide range of ... shares and distribution data. Why buy this report? Get a detailed picture of the Eyewear market; Pinpoint growth sectors and identify factors driving change; ...
February 2013
2 pages
Smartraoptics Co Ltd in Eyewear (Hong Kong, China)
US$ 150.00
SmarTraOptics strategically aims to expand outside Hong Kong and mainland China, with an emphasis on providing quality products and services. The company is ... distribution data. Why buy this report? Get a detailed picture of the Eyewear market; Pinpoint growth sectors and identify factors driving change; ...
February 2013
28 pages
HIV - KOL Insight and Consensus Outlook Modules
US$ 7,495.00
... FirstWord research is provided in two comprehensive modules: The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with ... Protease inhibitors CCR5 inhibitor Expert Opinion for Real World Insights The data and analysis in the report is enriched through the ...
February 2013
183 pages
SYMBIO - Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!
US$ 140.00
... FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought down SymBio pharma (4582 ... , please read our report released on 22nd February 2013 on SymBio titled “Growth Driver: PI3K Inhibitor’s Rigosertib & Cash to In-license More!”
February 2013
4 pages
Bristol-Myers Squibb Co in Consumer Health (World)
US$ 520.00
... BMS will pursue these remains to be seen. Euromonitor International’s Bristol-Myers Squibb Co in Consumer Health (World) Company Profile offers detailed strategic ... data. Why buy this report?: Get a detailed picture of the Consumer Health market; Pinpoint growth sectors and identify factors driving ...
February 2013
32 pages
Bristol-Myers Squibb Co in Consumer Health (Global)
US$ 572.00
Bristol-Myers Squibb Co, a US-based producer of pharmaceutical and consumer health products, is making increasingly definite steps away from consumer health in order to re-position itself as a bio-pharma ... International’s Bristol-Myers Squibb Co in Consumer Health (Global) Company Profile offers detailed strategic analysis of the company’s business, examining its performance in the Consumer Health industry ...
February 2013
32 pages
The Long Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living
US$ 3,196.00
... . These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report ... the Marketplace Competitors and Competitive Analysis Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are ...
February 2013
DR REDDY’S LAB - Growth to Slow Down on Higher Base, Margins to Remain Under Pressure
US$ 140.00
Dr Reddy’s Q3FY13 result was below our estimates as ... XL, ramp up of Fondaparinux (hospital segment) and Amoxil. We expect Dr. Reddy may participate in Vidaza opportunity which is due any time as an API ... US and Russia. We reiterate our market perform rating on Dr Reddy’s and retain out target price of Rs.1929.
February 2013
7 pages
INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!
US$ 140.00
... both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI). Despite limited clinical data in hand, PC and in vitro ... read our report released on 13th February 2013 on INFI titled “IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!”
February 2013
8 pages
Ear Care in Mexico
US$ 990.00
Ear care products to relieve pain are the most commonly used, followed by wax removal products. Euromonitor International's Ear Care in Mexico report offers a comprehensive guide ... data. Why buy this report? Get a detailed picture of the Ear Care market; Pinpoint growth sectors and identify factors driving change ...
February 2013
25 pages
GlaxoSmithKline México SA de CV in Consumer Health (Mexico)
US$ 150.00
GlaxoSmithKline México is one of the leading international pharmaceutical companies operating in the country, with a strategy of selling strong brands mostly to middle- and high-income consumers. As most international companies, GlaxoSmithKline has been operating in Mexico for decades, and manages very ...
February 2013
3 pages
Pfizer SA de CV in Consumer Health (Mexico)
US$ 150.00
... with OTC products taking second place. The recent acquisition of Wyeth by Pfizer Inc offered the company a better position within consumer health overnight: for example, Wyeth offers a comprehensive line of nutrition products, which Pfizer lacks. Both companies have been operating in the country for decades ...
February 2013
2 pages
Medicated Skin Care in the United Arab Emirates
US$ 990.00
... body) treatments, antipruritics, cold sore treatments and... Euromonitor International's Medicated Skin Care in United Arab Emirates report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
February 2013
26 pages
Therapeutic Class Report Overview - Hemophilia
US$ 2,000.00
Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used ...
February 2013
47 pages
Global and China Hemodialysis Industry Report, 2012-2013
US$ 2,200.00
... Science and Technology, etc. Given the huge potential in Chinese hemodialysis market, several listed companies have tapped into the field, ... landscape, import & export and development prediction of Chinese hemodialysis industry; Global and China hemodialysis equipment market segments and competition pattern ...
January 2013
91 pages
Brazilian Market for Wound and Tissue Management
US$ 6,995.00
... 2012, the total Brazilian market for wound and tissue management was valued at nearly $632 million. The Brazilian wound and tissue ... growth. Scope: This report pertains to a forecast period of 10 years (2008 – 2018) for Brazil. Report Contents: Competitor Analysis Identified Strategic Opportunities ...
January 2013
262 pages
European Wound and Tissue Management Markets
US$ 10,995.00
... wounds including surgical incisions, burns, and ulcers. The European wound and tissue management market is expected to be driven by an aging population and rising ... closure segments of the market. Technological developments such as negative pressure wound therapy and skin substitutes are also driving the market ...
January 2013
458 pages
Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)
US$ 800.00
... filled syringes a fast-growing alternative to vials for many parenteral drugs such as vaccines, anticoagulants and therapeutic proteins. The report titled “Global Prefilled Syringes Market: Trends & Opportunities (2012-2017)” provides an in-depth analysis of the global prefilled syringes market with major focus on biggest healthcare markets of U.S and Europe. It also ...
January 2013
78 pages
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
US$ 495.00
... Pharma do to maximise the credibility and visibility of its products? Overview The Path to Product Inclusion in Clinical Guidelines: Strategies for Success If you ... defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical
January 2013
49 pages
Cellular Therapy and Cord Blood 2013 Market Report
US$ 2,119.00
... is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences. In this ... . Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. Our coverage provides hard numbers ...
January 2013
172 pages
New Horizons in Healthcare Case Management: Benchmarks, Metrics and Models
US$ 299.00
... more than 90 figures and tables and answers more than 50 questions on patient-centered case management. Download the executive summary and complete table of contents for New Horizons in Healthcare Case Management: Benchmarks, Metrics and Models. Market research by the Healthcare ...
January 2013
200 pages
Personalized Medicine Market Opportunities
US$ 229.00
... and scientists are looking at options for curing AIDS as well with personalized medicines. Often described as the right treatment for the right ... technology platforms as well as the technological requirements for the personalized medicines market. Challenges facing the industry as well as a look at the key ...
January 2013
178 pages
CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion
US$ 140.00
With our conservative view on Revlimid – opportunity in EU (no approval in NDMM and Maintenance setting), reimbursement in China, and patent challenges; we expect net product sales’ CAGR (2013-17) of 17% (vs. CELG’s guidance: 19%) including risk adjusted late stage pipeline. We are positive on upcoming ...
January 2013
6 pages
ROCHE, Confidence building up on next gen. Rituxan (GA101)
US$ 90.00
Roche seems to be on track of delivering sustainable growth as it announced ... forward. With Perjeta and T-DM1 as well shaping up well, Roche is on a strong ground to sustain its revenues from Herceptin ... expected to reach the market in 2016, but by then, Roche would have GA101 on the market which would fend off ...
January 2013
3 pages
DISHMAN, Worry on Cash Flow Continues
US$ 140.00
... visibility of free cash flow generation, we continue to remain concerned about the fate of highly levered (operating and financial) business model of Dishman. The fact ... land clearly signifies that company is not generating sufficient free cash flow to service its debt. As the proposed sale of SEZ land has ...
January 2013
6 pages
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
US$ 2,000.00
... (CELG) M&A in Kinase Inhibitors in the last 5 years Related Milestones/catalysts in 2013-14 Combination Studies – PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological ...
January 2013
62 pages
GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory
US$ 140.00
nitial sales of newly added HIV products – Complera/ Eviplera (L, truvada + rilpivirine), Stribild (L in US, ... products contributed to the impressive 4Q12/FY13 results of Gilead. Positive data of Sofosbuvir (PMI, PhIII) in ... Through life cycle management of products for HIV, late stage HCV drugs and focus on ...
January 2013
8 pages
PHARMACYCLICS - Ibrutinib - Promising to Deliver More
US$ 140.00
... that there is meaningful upside on positive PhIII data and approval of Ibrutinib (PCI-32765, PhIII, BTK inhibitor, partnered with JNJ, PhIII ... of time, and iv) Patient tolerability including lack of bone marrow damage. Ibrutinib is a best-in-class among leukemia drugs, showed durable efficacy in Tx-naïve (TN) ...
January 2013
14 pages
Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
US$ 900.00
... on RTLS comprises: Quantification and analysis of the global RTLS market in the healthcare industry Current market size and forecast of the RTLS in the healthcare industry Illustration of drivers and trends Key factors affecting RTLS market in the healthcare industry Competitive Landscape: Profiles of ...
January 2013
20 pages
Worldwide Facial Rejuvenation Markets, 4th Edition
US$ 3,995.00
... on extensive interviews with senior management of top companies in the worldwide facial rejuvenation market. As part of its coverage, the 4th Edition includes ... pressures in the new millennium. While plastic surgery and cosmetic rejuvenation modalities offered this opportunity, it also came with a price and ...
January 2013
248 pages
Epigenetic Therapies and Technologies: World Market Prospects 2013-2023
US$ 2,400.00
... Our work explains, exploring many issues. What affects the application of epigenetics? Our report discusses issues and events affecting that science, ... and commercial possibilities. Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you To sum up, our investigation ...
January 2013
195 pages
Competitor Analysis: Enzyme Replacement Therapies
US$ 403.00
... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...
January 2013
74 pages
Closing the Loop: delivering real-world commercial benefit from closed-loop marketing
US$ 595.00
Your step-by-step guide to adapting to real time change. Over the past decade, closed loop marketing (CLM) has been a buzzword in pharma marketing ... actionable by themselves. This is where most companies are stuck in the closed-loop marketing cycle.” Marc Valdiviezo, former director of multichannel marketing, Pfizer.
December 2012
59 pages
Digital Health Quarterly 1Q 2013 2Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2012
17 pages
Digital Health Quarterly 2Q 2013 3Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2012
17 pages
Digital Health Quarterly 3Q 2013 4Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2012
17 pages
Digital Health Quarterly 4Q 2012 1Q 2013
US$ 1,500.00
The Market Tracker: Digital Health Quarterly offers in-depth analysis of the latest corporate news, industry events, passed and pending legislation, and government directives related to the digital health industry.
December 2012
19 pages
Global Healthcare Packaging Market 2013-2023
US$ 2,401.00
... methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments, as well as identifying the technological issues. ... prospects for established companies and new market entrants. How the Global Healthcare Packaging Market 2013-2023 report can benefit you ...
December 2012
175 pages
Research Report on China's High-end Medical Treatment Industry, 2013-2017
US$ 2,800.00
... are on the rather low level. The rich and foreigners in China attach importance to quality and privacy of medical services and they are ... is easier to create characteristics through equipment, technologies and services, China's high-end medical services are concentrated in these fields. However, investments in ...
December 2012
50 pages
Italy Flow Cytometry Market: Innovative Technologies and Emerging Business Opportunities
US$ 2,880.00
... report contains 142 pages, 15 tables and presents a comprehensive analysis of the Italian flow cytometry market, including: Major issues pertaining to the Italian ... . Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...
December 2012
142 pages
